checkAd

     133  0 Kommentare Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14 - Seite 3

    CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

    For more information, please contact:

    Capricor Media Contact:
    Raquel Cona
    KCSA Strategic Communications
    rcona@kcsa.com
    212.896.1204

    Capricor Investor Contact:
    Joyce Allaire
    LifeSci Advisors, LLC
    jallaire@lifesciadvisors.com
    617.435.6602

    Lesen Sie auch

    Capricor Company Contact:
    AJ Bergmann, Chief Financial Officer
    abergmann@capricor.com
    858.727.1755



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14 - Seite 3 Company to Host Conference Call, November 14, 2023, at 4:30 p.m. ETSAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) - Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based …